New Acne Treatments in 2026: What's Changed and What's Working

‍This article is educational and does not replace an evaluation by a board-certified dermatologist. If you have a concerning skin change, please book a visit.

If you have been reading about acne online in the last six months, you have probably seen headlines about clascoterone, triple-combination topicals, and live biotherapeutic products derived from skin bacteria. Some of this is real progress. Some of it is not yet something your dermatologist should prescribe. Acne treatment has moved faster in the last three years than in the previous decade, and the way dermatologists build a plan in 2026 is genuinely different from the way we built one in 2021. This guide explains what changed, what is still first-line, and what is coming but not yet ready. It is not a substitute for a visit with a board-certified dermatologist.

Why 2026 is a genuinely different treatment landscape

Three things shifted between 2020 and 2026. The first was the FDA approval of clascoterone 1% cream (Winlevi) in August 2020, the first truly new mechanism in topical acne therapy in roughly forty years (FDA, 2020). The second was the October 2023 approval of Cabtreo, a fixed-dose triple combination of clindamycin, adapalene, and benzoyl peroxide in a single cream, which changed what a "single topical" can deliver (FDA, 2023). The third is a dense pipeline of microbiome-targeted topicals and sebum-suppressing oral drugs that are now in Phase 2 and Phase 3 trials and are realistically within two to three years of availability.

At the same time, the American Academy of Dermatology updated its guidelines of care for acne vulgaris in 2024, formalizing fixed-dose triple combinations as a preferred option for moderate inflammatory acne and reinforcing shorter, narrower oral antibiotic courses as part of antimicrobial stewardship (AAD, 2024). None of this makes older treatments obsolete. It does change how a dermatologist sequences choices.

Treatment decisions depend on your individual skin, medical history, and goals. The information below describes how dermatologists evaluate options; it is not a prescription or a recommendation for any specific person.

First-line treatments that are still first-line

Before the new molecules, the evidence floor. For mild to moderate acne, the AAD continues to recommend topical retinoids (adapalene, tretinoin, trifarotene, tazarotene), benzoyl peroxide, and topical antibiotics in combination rather than alone. For moderate to severe inflammatory acne, oral antibiotics (doxycycline and minocycline, typically for 3 to 4 months) paired with a topical retinoid and benzoyl peroxide remain a standard combination. For severe, nodulocystic, or scarring acne, isotretinoin remains the most effective option available (AAD, 2024).

This matters because the newer options described below sit on top of that foundation, not next to it. A patient with inflammatory acne does not skip benzoyl peroxide to start a pipeline drug. The dermatologist's job is to match mechanism to the picture on the face.

New in topicals

Clascoterone (Winlevi): the first topical anti-androgen

What it is. Clascoterone is a topical androgen receptor antagonist, approved by the FDA in August 2020 for the treatment of acne vulgaris in patients 12 years and older (FDA, 2020). It binds to androgen receptors in sebocytes and hair follicles in the skin and blocks the downstream effects of dihydrotestosterone on sebum production and follicular inflammation.

What the evidence says. Two identical Phase 3 trials randomized about 1,400 patients with moderate to severe acne to twice-daily clascoterone 1% cream or vehicle for 12 weeks. Both trials met their co-primary endpoints of treatment success on the Investigator's Global Assessment and reduction in inflammatory and non-inflammatory lesions (Hebert et al., JAMA Dermatology, 2020).

Who it is appropriate for. Adult patients with a hormonal-pattern breakout (jawline, lower face, perimenstrual flaring) who cannot or prefer not to take oral spironolactone, including some men in whom spironolactone is not an option, and women with contraindications to hormonal therapy. It is also used as an add-on in patients on standard topicals whose hormonal axis appears to be a driver.

What to expect. Twice-daily application. Meaningful improvement is typically assessed at 8 to 12 weeks. Local irritation is possible but generally milder than with topical retinoids. Because very little systemic absorption occurs, clascoterone does not produce the systemic anti-androgen effects that limit oral spironolactone.

Triple-combination topicals: Cabtreo (IDP-126)

What it is. Cabtreo is a fixed-dose gel containing clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1%, approved by the FDA in October 2023 for acne vulgaris in patients 12 years and older (FDA, 2023). It is the first FDA-approved triple-combination topical acne product.

What the evidence says. In two Phase 3 trials, Cabtreo was compared head-to-head against each of the three possible dual-combination components and vehicle. The triple combination outperformed each dual combination on treatment success and lesion reduction at 12 weeks (Stein Gold et al., JAMA Dermatology, 2024).

Who it is appropriate for. Patients with moderate inflammatory or mixed acne who are candidates for combination topical therapy and who benefit from a single-step morning or evening routine. The fixed-dose vehicle reduces the compliance burden of layering three separate prescriptions.

What to expect. Once-daily application. Initial dryness, erythema, or peeling is common in the first 2 to 4 weeks. Benzoyl peroxide can bleach fabrics, which is worth knowing for pillowcases and towels. Sun protection is not optional.

Microbiome-focused formulations (live biotherapeutic C. acnes)

What it is. Rather than broadly killing bacteria, microbiome-targeted topicals aim to shift the composition of the facial microbiome. The most developed candidates are live biotherapeutic products that deliver non-acnegenic strains of Cutibacterium acnes or related species to the skin, displacing inflammatory strains. A separate line of work uses phage-based preparations targeted to specific C. acnes phylotypes.

What the evidence says. A 2026 peer-reviewed review in Anais Brasileiros de Dermatologia summarized the current evidence for topical probiotics, postbiotics, and live biotherapeutic C. acnes strains, noting promising early human data and a pipeline still largely in Phase 2 (Burckhardt-Bravo et al., 2026). No live biotherapeutic product for acne is FDA-approved as of May 2026.

Who it is appropriate for. This is a watch-and-wait category. Over-the-counter "probiotic" skincare products should not be confused with prescription live biotherapeutic products in clinical development. The evidence for most OTC formulations is limited.

What to expect. If you see advertising for "microbiome acne cream" in 2026, it is almost certainly a cosmetic, not a prescription live biotherapeutic. The first true live biotherapeutics will arrive by prescription through a dermatologist.

Pipeline worth knowing

Two named pipeline drugs have enough human data to be worth explaining, even though neither is currently prescribable in the United States.

DMT-310 (topical botanical, Phase 3)

DMT-310 is a once-weekly topical preparation derived from a botanical powder, studied for moderate to severe acne. A Phase 2b trial reported significant reductions in inflammatory and non-inflammatory lesions, and Phase 3 trials are in progress as of early 2026. The once-weekly dosing schedule is unusual in topical acne therapy and, if the Phase 3 results hold, would be a compliance advantage.

Denifanstat / ASC40 (oral FASN inhibitor)

Denifanstat is an oral inhibitor of fatty acid synthase (FASN), the enzymatic engine for sebum lipid production. In a 2024 Phase 3 trial in patients with moderate to severe acne, denifanstat 50 mg once daily significantly reduced inflammatory and non-inflammatory lesion counts and improved Investigator's Global Assessment scores at 12 weeks (Eichenfield et al., JAMA Dermatology, 2024). If approved, it would be the first oral sebum-suppressing acne drug whose mechanism sits outside the isotretinoin and hormonal therapy categories. It is not currently FDA-approved.

Where oral antibiotics fit now

Oral antibiotics are still appropriate for moderate to severe inflammatory acne, and doxycycline and minocycline are still the most used. What has changed is how long we prescribe them and how we pair them. The 2024 AAD guidelines and broader antimicrobial stewardship principles converge on three points: keep courses to 3 to 4 months where possible, always pair an oral antibiotic with a topical retinoid and benzoyl peroxide to reduce resistance, and reassess rather than extend if results stall (AAD, 2024). Sarecycline, a narrower-spectrum tetracycline approved in 2018, is specifically designed to reduce collateral impact on the gut and skin microbiomes and is a reasonable choice when that matters clinically.

Hormonal acne treatment updates

For adult women whose breakouts follow a hormonal pattern, two tools remain central. Oral spironolactone, used off-label at doses typically ranging from 50 to 200 mg daily, continues to have robust observational evidence and favorable dermatology-society guidance (AAD, 2024). Combined oral contraceptives that contain an estrogen component can reduce acne in appropriately selected patients; several formulations are FDA-approved for acne. In 2026, the shift is largely in layering: clascoterone topical can be used alongside spironolactone in patients who need more coverage on specific facial zones, and clascoterone is an option for patients who do not tolerate oral therapy.

Isotretinoin in 2026

Isotretinoin remains the most effective treatment available for severe, nodulocystic, or scar-prone acne and for moderate acne that has failed multiple other therapies (AAD, 2024). The iPLEDGE program, which applies to patients who can become pregnant because isotretinoin is a potent teratogen, continues to require registration, monthly pregnancy testing, and attested contraception.

Monitoring practices have changed modestly. Many dermatologists now order baseline and one follow-up set of labs (liver enzymes, lipids) rather than monthly labs for every patient, following evidence that frequent lab monitoring changes management infrequently in otherwise healthy patients. Dose totals are still commonly guided by cumulative exposure, though extended low-dose protocols have become more common for adult patients with chronic, lower-grade disease.

Energy-based options

Two device categories are worth naming. Blue light and red light photodynamic approaches have longstanding evidence for mild to moderate inflammatory acne, and AviClear, a 1726 nm laser approved by the FDA in 2022 for mild to moderate acne, targets and heats sebaceous glands to reduce sebum output. These are not first-line for most patients. They are options when topicals and orals are not tolerated, not desired, or not sufficient, and they are best discussed with a dermatologist familiar with the specific device and its trial data.

Houston-specific factors

Acne does not change fundamentally by geography, but skincare does. Houston sits in a subtropical climate with average relative humidity close to 75% year-round and a UV index that does not fall below moderate in any month (National Weather Service Houston/Galveston). Three practical implications come up repeatedly at Bayou City Dermatology.

• Vehicle choice matters. A heavy cream that works beautifully in a drier climate can feel occlusive and trigger comedones in Houston summer. Lighter lotions, gels, or gel-cream hybrids are often better tolerated.
• Sweat and skincare layering interact. If you apply a benzoyl peroxide wash, a retinoid, a topical antibiotic, a moisturizer, and a sunscreen, and then sweat during a morning walk, the combination can drive irritation even when each product alone would be fine. Simplification usually helps.
• Year-round UV exposure shapes retinoid use. Adapalene, tretinoin, and benzoyl peroxide can all increase photosensitivity. Daily broad-spectrum mineral sunscreen is not optional, not seasonal, and not a preference in this city.

Building a 2026 acne plan with your dermatologist

A 2026 acne plan generally starts with a short conversation about pattern (comedonal, inflammatory, nodulocystic), distribution (forehead, U-zone, jawline), history (what has been tried, for how long, with what result), and goals (clearance speed, scarring prevention, tolerability). From there, most plans involve a topical regimen (often a fixed-dose combination), a decision about whether an oral is warranted, and, for hormonal patterns, a decision about spironolactone or clascoterone. Follow-up at 8 to 12 weeks is standard; that is when the regimen is adjusted. If you are a patient at Bayou City Dermatology's acne treatment program, the plan is individualized at that first visit.

For scarring, treatment is a second conversation. See our pages on acne scar treatment and microneedling for what we offer after active acne is controlled.

Frequently Asked Questions

What is the newest prescription acne medication in 2026?

The most significant recent prescription additions are clascoterone 1% cream (Winlevi), the first topical anti-androgen approved by the FDA for acne, and the fixed-dose triple-combination topical of clindamycin, adapalene, and benzoyl peroxide (Cabtreo, IDP-126), approved by the FDA in 2023. Several pipeline drugs, including DMT-310 and denifanstat, are in later-phase trials and are not yet available.

Does clascoterone (Winlevi) work for adult acne?

Clascoterone is FDA-approved for patients 12 years and older with acne vulgaris. It works by blocking androgen receptors in the skin, which reduces sebum production and inflammation. It is an option for adults whose acne has a hormonal pattern, including women who cannot or do not wish to take oral spironolactone.

Is the acne microbiome the same as gut bacteria?

No. The acne-relevant microbiome refers to the bacteria living on and in facial skin, most notably Cutibacterium acnes. It is a distinct ecosystem from the gut. Microbiome-targeted acne topicals aim to shift the balance of C. acnes strains and related species on the skin rather than to change the gut flora.

How does Houston's humidity affect acne?

Persistent high humidity increases sweat and surface oiliness, can worsen occlusion under sunscreens and cosmetics, and makes some patients more prone to inflammatory breakouts. It does not change which prescriptions work, but it affects vehicle choice (lighter lotions or gels over heavier creams) and skincare layering.

Is isotretinoin still used in 2026?

Yes. Isotretinoin remains the most effective treatment for severe, nodulocystic, and scarring acne, and for moderate acne that has failed other therapies. Monitoring protocols have evolved, and the iPLEDGE program continues to require specific steps for patients who can become pregnant.

The acne landscape in 2026 rewards patience and specificity. The newer molecules are real, but they are tools, not replacements for a plan. Response varies, and the right combination for a 16-year-old with comedonal acne is not the right combination for a 34-year-old with perimenstrual jawline flares. If you are ready to talk through what fits your skin, book a consultation at Bayou City Dermatology or read more about our dermatology services.